ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Bosutinib is a breakpoint cluster region-Abelson gene (BCR-ABL) tyrosine kinase inhibitor (TKI) used for the treatment of chronic myeloid leukemia (CML).